Alex Adjei, MD, PhD

Appointed
2022

Education & Fellowships

Fellowship - John Hopkins Hospital
Medical Oncology
Baltimore, MD United States
1995

Residency - Howard University Hospital
Internal Medicine
Washington, DC
1992

Internship - Howard University Hospital
Internal Medicine
Washington, DC
1990

Graduate School - University of Alberta
Pharmacology
Edmonton, Alberta Canada T6G2R, Canada
1989

Internship - University of Ghana Medical School
Accra,
1983

Medical Education - University of Ghana Medical School
Accra, Ghana
1982

Undergraduate - University of Ghana
First university year before medical school. No degree awarded
Accra, Ghana
1977

Professional Highlights

• Prior to taking this position, he was Professor of Oncology, Professor of Pharmacology and Director of Early Cancer Therapeutics at Mayo Clinic in Rochester, Minnesota. 

  He was co-chair of the National Cancer Institute's Thoracic Malignancies Steering Committee until 2021, recently served as a member of the National Institute of Health's Blue Ribbon Panel evaluating quality of grant reviews by Oncology Study Sections and also as a member of the National Academy of Science, Engineering and Medicine's Committee on Diagnosis and Treatment of Adult Cancers. He is currently a member of the National Cancer Institute's Board of Scientific Counselors .

  He is editor-in-chief of the Journal of Thoracic Oncology, and the JTO Clinical and Research Reports, and has authored over 300 peer-reviewed publications and edited two books. His academic expertise and research is in regulatory science, drug development, early phase trials, pharmacogenetics, novel therapies for lung cancer and academic publishing.

Certifications

• Internal Medicine - Medical Oncology

Awards & Honors

• He received the first American Society of Clinical Oncology Drug Development Research Professorship 2012-2017, in recognition of his mentorship and work in cancer drug development. He also received the International Associations for the Study of Lung Cancer Award for Distinguished Service in Lung Cancer Research and Mentorship, and the European Society of Medical Oncology Lifetime Achievement Award, in 2020 and 2021 respectively.

See publications for Alex Adjei, MD, PhD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 3/28/2024, Dr. Adjei has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.